Mechanism of formation and significance of antimitochondrial autoantibodies in the pathogenesis of primary biliary cholangitis

Abstract

Primary biliary cholangitis (PBC) is a chronic cholestatic progressive liver disease associated with cholangiopathies. The detection of antimitochondrial autoantibodies (AMAs) plays an important role in the diagnosis of classical PBC. AMAs are formed against the antigenic component associated with the dihydrolipoyl transacetylase of pyruvate dehydrogenase complex (E2 PDC) localized on the inner membrane of mitochondria. The loss of immune tolerance of E2 PDC in PBC is thought to be the cause of the mechanism of AMA formation and immune-mediated destruction of biliary epithelial cells (BECs) of the small- and medium-sized intrahepatic bile ducts. E2 PDC is not only present in BECs, but is also abundant in the mitochondria of all nucleated cells. The question remains as to why E2 PDC of only small BECs is the target of autoimmune attack. There is no evidence that AMAs have a deleterious effect on BECs. New scientific data has emerged that explains the damage to BECs in PBC by the defect of the biliary bicarbonate (HCO₃^–) “umbrella” that protects BECs from the detergent action of bile acids under physiological conditions. Disruption of HCO₃^– production by BECs in PBC leads to changes in the pH of hepatic bile, accompanied by accumulation of bile acids in the small BECs. The detergent action of bile acids leads to damage of membrane structures of BECs and their apoptosis, development of ductulopenia, and intrahepatic cholestasis. For the first time, it has been suggested that under the influence of bile acids, the E2 PDC antigen may undergo conformational changes that alter its immunological properties. E2 PDC becomes a neoantigen that is recognized by the normal (“healthy”) immune system as a foreign antigen, leading to the production of AMAs. For the first time, the authors of this review provide an explanation for why only small BECs are damaged in PBC.

Keywords

Primary biliary cholangitis / cholestasis / antimitochondrial autoantibodies / dihydrolipoyl transacetylase of pyruvate dehydrogenase complex / biliary epithelial cells

References

[1] Floreani A, Gabbia D, De Martin S. Primary biliary cholangitis: primary autoimmune disease or primary secretory defect. Expert Rev Gastroenterol Hepatol. 2023; 17: 863-70.

[2] Reshetnyak VI, Maev IV. New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage. World J Gastroenterol. 2023; 29: 5292-304.

[3] van Niekerk J, Kersten R, Beuers U. Role of Bile Acids and the Biliary HCO₃^- Umbrella in the Pathogenesis of Primary Biliary Cholangitis . Clin Liver Dis. 2018; 22: 457-79.

[4] Rigopoulou EI, Bogdanos DP. Role of autoantibodies in the clinical management of primary biliary cholangitis. World J Gastroenterol. 2023; 29: 1795-810.

[5] Aseem SO, Hylemon PB, Zhou H. Bile Acids and Biliary Fibrosis. Cells. 2023; 12: 792.

[6] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017; 67: 145-72.

[7] Smyk DS, Rigopoulou EI, Lleo A, Abeles RD, Mavropoulos A, Billinis C, et al. Immunopathogenesis of primary biliary cirrhosis: an old wives’ tale. Immun Ageing. 2011; 8: 12.

[8] Hu S, Zhao F, Wang Q, Chen WX. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clin Chem Lab Med. 2014; 52: 1533-42.

[9] Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology. 1991; 100: 822-33.

[10] Neuberger J, Thomson R. PBC and AMA-what is the connection? Hepatology. 1999; 29: 271-6.

[11] Chen R, Tang R, Ma X, Gershwin ME. Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis. Clin Liver Dis. 2022; 26: 583-611.

[12] Novikova IA, Khoduleva SA. Autoimmune diseases: diagnosis and principles of therapy. Minsk: Higher School; 2017.

[13] Ma WT, Chen DK. Immunological abnormalities in patients with primary biliary cholangitis. Clin Sci (Lond). 2019; 133: 741-60.

[14] Doniach D, Roitt IM, Walker JG, Sherlock S. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol. 1966; 1: 237-62.

[15] Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol. 2021; 27: 1-21.

[16] Tanaka A, Leung PSC, Gershwin ME. The Genetics and Epigenetics of Primary Biliary Cholangitis. Clin Liver Dis. 2018; 22: 443-55.

[17] Tanaka A, Leung PS, Gershwin ME. Environmental basis of primary biliary cholangitis. Exp Biol Med (Maywood). 2018; 243: 184-9.

[18] Ma WT, Chang C, Gershwin ME, Lian ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. J Autoimmun. 2017; 83: 95-112.

[19] Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015; 386: 1565-75.

[20] Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012; 38: J109-19.

[21] Colapietro F, Lleo A, Generali E. Antimitochondrial Antibodies: from Bench to Bedside. Clin Rev Allergy Immunol. 2022; 63: 166-77.

[22] Mitri IE, Kaaouch H, Ouboks M, Ballil O. The contribution of antinuclear antibodies in Primary Biliary Cholangitis (PBC): An experience from the immunology laboratory at University Hospital Center Hassan II, Fes, Morocco. Qatar Med J. 2023; 2023: 27.

[23] Ma D, Ma J, Zhao C, Tai W. Reasons why women are more likely to develop primary biliary cholangitis. Heliyon. 2024; 10: e25634.

[24] Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis: Three-year results. J Hepatol. 1992; 15: 336-44.

[25] Imam MH, Talwalkar JA, Lindor KD. Clinical management of autoimmune biliary diseases. J Autoimmun. 2013; 46: 88-96.

[26] Lleo A, Leung PSC, Hirschfield GM, Gershwin EM. The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. Semin Liver Dis. 2020; 40: 034-48.

[27] Floreani A, Franceschet I, Cazzagon N, Spinazzè A, Buja A, Furlan P, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015; 48: 192-7.

[28] Floreani A, Cazzagon N. PBC and related extrahepatic diseases. Best Pract Res Clin Gastroenterol. 2018; 34-35: 49-54.

[29] Selmi C, Gershwin ME. Chronic Autoimmune Epithelitis in Sjögren’s Syndrome and Primary Biliary Cholangitis: A Comprehensive Review. Rheumatol Ther. 2017; 4: 263-79.

[30] Coppel RL, McNeilage LJ, Surh CD, Van de Water J, Spithill TW, Whittingham S, et al. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A. 1988; 85: 7317-21.

[31] Tana MM, Shums Z, Milo J, Norman GL, Leung PS, Gershwin ME, et al. The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis. Am J Clin Pathol. 2015; 144: 601-6.

[32] Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS, et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology. 1997; 25: 6-11.

[33] Feng L, Dong K, Zhang X, Ma B, Chen L, Yang Q, et al. Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China. PLoS One. 2020; 15: e0242164.

[34] Lenci I, Carnì P, Milana M, Bicaj A, Signorello A, Baiocchi L. Sequence of events leading to primary biliary cholangitis. World J Gastroenterol. 2023; 29: 5305-12.

[35] Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants . N Engl J Med. 2009; 360: 2544-55.

[36] Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO₃^- umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies . Hepatology. 2010; 52: 1489-96.

[37] Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, et al. A biliary HCO₃^- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes . Hepatology. 2012; 55: 173-83.

[38] Maillette de Buy Wenniger LJ, Hohenester S, Maroni L, van Vliet SJ, Oude Elferink RP, Beuers U. The Cholangiocyte Glycocalyx Stabilizes the ‘Biliary HCO₃^- Umbrella’: An Integrated Line of Defense against Toxic Bile Acids . Dig Dis. 2015; 33: 397-407.

[39] Tabibian JH, Masyuk AI, Masyuk TV, O’Hara SP, LaRusso NF. Physiology of cholangiocytes. Compr Physiol. 2013; 3: 541-65.

[40] Matsubara T, Kozaka K, Matsui O, Nakanuma Y, Uesaka K, Inoue D, et al. Peribiliary glands: development, dysfunction, related conditions and imaging findings. Abdom Radiol (NY). 2020; 45: 416-36.

[41] Banales JM, Prieto J, Medina JF. Cholangiocyte anion exchange and biliary bicarbonate excretion. World J Gastroenterol. 2006; 12: 3496-511.

[42] Masyuk AI, Masyuk TV, Tietz PS, Splinter PL, LaRusso NF. Intrahepatic bile ducts transport water in response to absorbed glucose. Am J Physiol Cell Physiol. 2002; 283: C785-91.

[43] Kanno N, LeSage G, Glaser S, Alpini G. Regulation of cholangiocyte bicarbonate secretion. Am J Physiol Gastrointest Liver Physiol. 2001; 281: G612-25.

[44] Marzioni M, Glaser SS, Francis H, Phinizy JL, LeSage G, Alpini G. Functional heterogeneity of cholangiocytes. Semin Liver Dis. 2002; 22: 227-40.

[45] Carpino G, Cardinale V, Onori P, Franchitto A, Berloco PB, Rossi M, et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat. 2012; 220: 186-99.

[46] Prieto J, Qian C, García N, Díez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology. 1993; 105: 572-8.

[47] Medina JF, Martínez-Ansó, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology. 1997; 25: 12-7.

[48] Melero S, Spirlì C, Zsembery A, Medina JF, Joplin RE, Duner E, et al. Defective regulation of cholangiocyte Cl^-/HCO₃^- and Na⁺/H⁺ exchanger activities in primary biliary cirrhosis . Hepatology. 2002; 35: 1513-21.

[49] Ananthanarayanan M, Banales JM, Guerra MT, Spirli C, Munoz-Garrido P, Mitchell-Richards K, et al. Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506. J Biol Chem. 2015; 290: 184-96.

[50] Banales JM, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, et al. Up-regulation of microRNA 506 leads to decreased Cl^-/HCO₃^- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis . Hepatology. 2012; 56: 687-97.

[51] Chang JC, Go S, Verhoeven AJ, Beuers U, Oude Elferink RPJ. Role of the bicarbonate-responsive soluble adenylyl cyclase in cholangiocyte apoptosis in primary biliary cholangitis; a new hypothesis. Biochim Biophys Acta Mol Basis Dis. 2018; 1864: 1232-9.

[52] Minagawa N, Nagata J, Shibao K, Masyuk AI, Gomes DA, Rodrigues MA, et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology. 2007; 133: 1592-602.

[53] Concepcion AR, Lopez M, Ardura-Fabregat A, Medina JF. Role of AE2 for pH_i regulation in biliary epithelial cells . Front Physiol. 2014; 4: 413.

[54] Reshetnyak VI, Maev IV. Mechanism of Small Cholangiocyte Injury in Primary Biliary Cholangitis. Эффективная фармакотерапия. 2024; 20: 72-84. Russian.

[55] Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine Growth Factor Rev. 2016; 28: 53-61.

[56] Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol. 2015; 62: S15-24.

[57] Strazzabosco M. Transport systems in cholangiocytes: their role in bile formation and cholestasis. Yale J Biol Med. 1997; 70: 427-34.

[58] Saipiyeva D, Askarov M, Tuganbekov T, Rustemova K, Grigorevsky V, Dossatayeva G, et al. Antimitochindrial and antinuclear antibodies in primary biliary cholangitis. J Clin Med Kaz. 2019; 2: 16-22. Russian.

[59] Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021; 113: 170-84.

[60] Ichas F, Jouaville LS, Mazat JP. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. Cell. 1997; 89: 1145-53.

[61] Szalai G, Krishnamurthy R, Hajnóczky G. Apoptosis driven by IP₃-linked mitochondrial calcium signals . EMBO J. 1999; 18: 6349-61.

[62] Csordás G, Thomas AP, Hajnóczky G. Quasi-synaptic calcium signal transmission between endoplasmic reticulum and mitochondria. EMBO J. 1999; 18: 96-108.

[63] Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol. 2015; 78: 129-41.

[64] Berg CP, Stein GM, Keppeler H, Gregor M, Wesselborg S, Lauber K. Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis. 2008; 13: 63-75.

[65] Chang JC, Go S, de Waart DR, Munoz-Garrido P, Beuers U, Paulusma CC, et al. Soluble Adenylyl Cyclase Regulates Bile Salt-Induced Apoptosis in Human Cholangiocytes. Hepatology. 2016; 64: 522-34.

[66] Surh CD, Roche TE, Danner DJ, Ansari A, Coppel RL, Prindiville T, et al. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. Hepatology. 1989; 10: 127-33.

[67] Gulamhusein AF, Hirschfield GM. Pathophysiology of primary biliary cholangitis. Best Pract Res Clin Gastroenterol. 2018; 34-35: 17-25.

[68] Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest. 1998; 102: 1831-40.

[69] Rahmatullah M, Gopalakrishnan S, Andrews PC, Chang CL, Radke GA, Roche TE. Subunit associations in the mammalian pyruvate dehydrogenase complex. Structure and role of protein X and the pyruvate dehydrogenase component binding domain of the dihydrolipoyl transacetylase component. J Biol Chem. 1989; 264: 2221-7.

[70] Fussey SP, Bassendine MF, James OF, Yeaman SJ. Characterisation of the reactivity of autoantibodies in primary biliary cirrhosis. FEBS Lett. 1989; 246: 49-53.

[71] Surh CD, Coppel R, Gershwin ME. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. J Immunol. 1990; 144: 3367-74.

[72] Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol. 2008; 14: 3328-37.

[73] Erice O, Munoz-Garrido P, Vaquero J, Perugorria MJ, Fernandez-Barrena MG, Saez E, et al. MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. Hepatology. 2018; 67: 1420-40.

[74] Ohmori H, Yamauchi T, Yamamoto I. Augmentation of the antibody response by lipoic acid in mice I. Analysis of the mode of action in an in vitro cultures system. Jpn J Pharmacol. 1986; 42: 135-40.

[75] Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol. 2006; 177: 4481-7.

[76] Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009; 49: 871-9.

[77] Lleo A, Maroni L, Glaser S, Alpini G, Marzioni M. Role of cholangiocytes in primary biliary cirrhosis. Semin Liver Dis. 2014; 34: 273-84.

[78] Surh CD, Ahmed-Ansari A, Gershwin ME. Comparative epitope mapping of murine monoclonal and human autoantibodies to human PDH-E2, the major mitochondrial autoantigen of primary biliary cirrhosis. J Immunol. 1990; 144: 2647-52.

[79] Krams SM, Surh CD, Coppel RL, Ansari A, Ruebner B, Gershwin ME. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology. 1989; 9: 411-6.

[80] Rieger R, Leung PS, Jeddeloh MR, Kurth MJ, Nantz MH, Lam KS, et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun. 2006; 27: 7-16.

[81] Leung PS, Park O, Tsuneyama K, Kurth MJ, Lam KS, Ansari AA, et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol. 2007; 179: 2651-7.

[82] Wakabayashi K, Yoshida K, Leung PS, Moritoki Y, Yang GX, Tsuneyama K, et al. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol. 2009; 155: 577-86.

[83] Wakabayashi K, Lian ZX, Leung PS, Moritoki Y, Tsuneyama K, Kurth MJ, et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology. 2008; 48: 531-40.

[84] Leung PS, Quan C, Park O, Van de Water J, Kurth MJ, Nantz MH, et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol. 2003; 170: 5326-32.

[85] Wang J, Budamagunta MS, Voss JC, Kurth MJ, Lam KS, Lu L, et al. Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. J Immunol. 2013; 191: 2126-33.

[86] Naiyanetr P, Butler JD, Meng L, Pfeiff J, Kenny TP, Guggenheim KG, et al. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J Autoimmun. 2011; 37: 209-16.